NCT04081363View on ClinicalTrials.gov

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

December 21, 2019

Study Completion Date

December 21, 2019

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Centanafadine

Extended-release and immediate-release capsules.

Trial Locations (1)

14618

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04081363 - Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter